Metraipolis › archive › dc_ebe7dbcf0b0e
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis — Europe PMC PMID:42081291
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42081291
- DOI
- 10.1093/oncolo/oyag172
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T22:50:38.741Z
- SHA-256 of the archived text
d0d0af665608b3aeeacece23ce493563344feab3907efe81f61c300274045073- Stable URL of this page
https://metraipolis.com/documento/dc_ebe7dbcf0b0e
How to cite
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis — Europe PMC PMID:42081291 — Europe PMC (en), https://europepmc.org/article/MED/42081291 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ebe7dbcf0b0e (Metraipolis archive dc_ebe7dbcf0b0e, sha256 d0d0af665608b3aeeacece23ce493563344feab3907efe81f61c300274045073)
BibTeX
@misc{dcebe7dbcf0b0e,
title = {Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis — Europe PMC PMID:42081291},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42081291},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ebe7dbcf0b0e; sha256 d0d0af665608b3aeeacece23ce493563344feab3907efe81f61c300274045073},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42081291. Agents can read the archived copy with the MCP tool read_document.